Understanding the fine points of inter partes review

被引：0

|

作者：

Blount, Jennifer ^{[1
]}

机构：

[1] ImmunoGen Inc, Waltham, MA USA

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2014年 / 248卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

15-CHAL

引用

收藏

页数：1

相关论文

共 50 条

[31] Obligations Erga Omnes (Partes) and the Participation of Third States in Inter-State Litigation
McGarry, Brian
[J]. LAW & PRACTICE OF INTERNATIONAL COURTS AND TRIBUNALS, 2023, 22 (02): : 273 - 300
[32] Contested applications to remove executors-quite unlike ordinary inter partes litigation
Bishop, Toby
[J]. TRUSTS & TRUSTEES, 2019, 25 (09) : 910 - 918
[33] FORTRAN FINE POINTS
CLOVER, WJ
[J]. DR DOBBS JOURNAL, 1993, 18 (04): : 12 - &
[34] FINE POINTS IN THE ER
FELICIANO, DV
[J]. EMERGENCY MEDICINE, 1982, 14 (13) : 287 - &
[35] The fine points of taping
Brock, Gordon
[J]. CANADIAN JOURNAL OF RURAL MEDICINE, 2018, 23 (02) : 52 - 55
[36] Fine points of federalism
Heffernan, K
[J]. ABA JOURNAL, 2000, 86 : 14 - 14
[37] Fine points of federalism
Berg, ME
[J]. ABA JOURNAL, 2000, 86 : 14 - 14
[38] THE FINE POINTS OF CHIPS
BARDEN, RA
[J]. IEEE SPECTRUM, 1983, 20 (09) : 6 - 6
[39] FINE POINTS OF THE LAW
KAPPEN, PM
[J]. JOURNAL OF SOIL AND WATER CONSERVATION, 1984, 39 (05): : 282 - 282
[40] How the new Patent Trial and Appeal Board rules impact the practice of inter partes reviews
Hsing, Benjamin C.
French-Brown, Wanda
[J]. PHARMACEUTICAL PATENT ANALYST, 2016, 5 (05) : 281 - 283

← 1 2 3 4 5 →